December 2022 in “IntechOpen eBooks” This source evaluates the clinical effectiveness of 308 nm monochromatic excimer phototherapy in treating moderate-to-severe alopecia areata, noting that both laser and lamp methods show promise without significant risks.
March 2025 in “Pediatric Rheumatology” This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.
April 2024 in “International journal of molecular sciences” This source reports that for treating keloids and hypertrophic scars, combination pharmacotherapy targeting multiple sites is generally more effective than using a single drug, though outcomes of individual therapies vary and the development of satisfying treatments is ongoing.
August 2010 in “Oncology Times” This article discusses the approval and perceived potential of Provenge, a new prostate cancer vaccine, highlighting its capability to extend survival in certain patients while also noting ongoing debates about its cost and mechanisms; it reports no new clinical results.
9 citations
,
July 2024 in “Toxins” This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.
22 citations
,
August 2013 in “Facial Plastic Surgery Clinics of North America” A cosmetic procedure can lower the hairline by up to 10 cm, with high satisfaction but potential for temporary sensation loss and rare risks.
6 citations
,
January 2023 in “Annals of Dermatology” This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.
8 citations
,
February 2020 in “Fertility and Sterility” This study discusses treatment approaches for refractory Asherman syndrome, highlighting the potential role of CD133+ bone marrow-derived stem cells in conjunction with hysteroscopy for endometrial regeneration and improved pregnancy outcomes.
In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.
January 2026 in “Ciencia Latina Revista Científica Multidisciplinar” This study reports on a 14-year-old male with refractory diffuse alopecia areata who achieved full hair density restoration after three monthly sessions of microneedling combined with triamcinolone, dutasteride, and synthetic exosome treatment, highlighting exosomes' potential for enhancing traditional therapies in autoimmune hair loss cases.
2 citations
,
July 2024 in “Cureus” This review discusses the potential benefits of using autologous endometrial cells and PRP via hysteroscopic injections to improve pregnancy outcomes in ART, particularly in individuals with refractory thin endometrium, but reports no new clinical results.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.
1 citations
,
May 2025 in “The Journal of Rheumatology” In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.
April 2026 in “Dermatology and Therapy” This study reviews the efficacy and safety of advanced therapies like TNFα inhibitors and IL-17/IL-23 inhibitors for dissecting cellulitis of the scalp, finding TNFα inhibitors particularly effective for severe or refractory cases, although prospective validation is needed for early intervention benefits.
In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.
July 2025 in “Revista Eletrônica Acervo Científico” This integrative literature review found that hydroxychloroquine may stabilize inflammatory scarring autoimmune alopecias like frontal fibrosing alopecia, especially when combined with other therapies, while its effectiveness in non-scarring alopecias appears inconsistent and is limited to refractory cases.
May 2025 in “The Journal of Rheumatology” This case report highlights the rare occurrence of overlapping syndromes including SLE, RA, and AAV in a patient with discoid lupus erythematosus, noting the persistent role of prior viral infection remains unclear.
May 2025 in “The Journal of Rheumatology” In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.
November 2025 in “SKIN The Journal of Cutaneous Medicine” In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.
11 citations
,
May 2009 in “Actas Dermo-Sifiliográficas” This review discusses various therapeutic options for alopecia areata and reports no new clinical results; treatments may manage symptoms but do not cure the condition.
3 citations
,
August 2024 in “Cureus” In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.
1 citations
,
September 2023 in “Journal of drugs in dermatology” This article discusses the perspectives of clinicians and patients on alopecia areata, an autoimmune disorder with significant psychosocial impacts, highlighting the unpredictability and limited effectiveness of current treatments as well as the key unmet needs and gaps in care.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” This review discusses the various off-label treatments for alopecia areata, highlighting that these therapies may promote hair growth but are not curative.
February 2021 in “Journal of pharmaceutical and biological sciences” This article reviews multiple treatments for alopecia areata, highlighting their variable efficacy and safety without any being curative; it reports no new clinical findings.
This review discusses various treatment options for alopecia areata, focusing on manipulating the immune response around hair follicles, but reports no new clinical results.
24 citations
,
June 2019 in “Journal of Cosmetic Dermatology” This study found that microneedling improved hair density and thickness with minimal side effects in patients with androgenetic alopecia and telogen effluvium.
10 citations
,
January 2018 in “International Journal of Trichology” In this study, researchers retrospectively analyzed five children with extensive and refractory alopecia areata treated with mesalazine, observing complete hair regrowth in all patients without side effects, suggesting potential benefits of this treatment combination, though controlled studies are needed for confirmation.
6 citations
,
April 2024 in “Health Science Reports” This study found that young patients with severe AA are more prone to nail abnormalities such as pitting and leukonychia, with koilonychia and red spots lunula in more severe cases.
67 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses the causes, associated conditions, and treatment options for alopecia areata, such as corticosteroids and wigs, but reports no new clinical findings.
36 citations
,
May 2011 in “Dermatologic therapy” This review discusses topical and intralesional treatments for alopecia areata, providing a management strategy based on patient age and disease severity, but reports no new clinical results.